An Overview of Pericardial Mesothelioma

Table of Contents
View All
Table of Contents

Pericardial mesothelioma is a cancer that begins in the membranes (mesothelium) that surround the heart (the pericardium). It is a very rare tumor with nonspecific symptoms (such as chest pain) that can easily be confused with other causes. The diagnosis is also challenging, and often requires a combination of imaging, echocardiogram, and a biopsy.

Unlike pleural mesothelioma that is strongly associated with asbestos exposure, the causes of pericardial mesothelioma are uncertain. Treatment options may include surgery for cancers that have not spread, chemotherapy, or clinical trials.

doctorconsult patient with heart problems
VeryUlissa / Getty Images


Mesothelioma is a tumor that arises in tissues called mesothelium, and may occur in four primary regions of the body:

  • Pleural mesothelioma is a tumor of the lining of the lungs (the pleura) and accounts for 65% to 70% of these cancers.
  • Peritoneal mesothelioma is a cancer of the membranes lining the abdomen (the peritoneum) and makes up 30% of mesotheliomas.
  • Testicular mesothelioma is a cancer of the lining of the testicles (the tunica vaginalis) and makes up less than 1% of mesotheliomas.
  • Pericardial mesothelioma is responsible for 1% to 2% of mesotheliomas.

While pericardial mesothelioma is similar to other forms of mesothelioma in some ways, there appear to be important differences as well. The median age of diagnosis is age 55, though the cancer can be found at any age.

Case reports of people as young as age 19 and 28 are found in the literature. The cancer occurs more often in men, but women represent a higher proportion of cases than is seen with pleural mesothelioma.

Symptoms of Pericardial Mesothelioma

The signs of pericardial mesothelioma are usually nonspecific, with the most common being chest pain and shortness of breath.

Other symptoms may include swelling of the legs (edema), palpitations, unintentional weight loss, and fatigue.

The symptoms are more easily understood by picturing what is happening in the heart. As the tumor grows in the lining of the heart, it restricts that ability of the heart to fill fully and contract normally (constrictive pericarditis).

The presence of the tumor itself can lead to pain (especially chest pain with a deep breath), and the restriction of heart motion can lead to symptoms of heart failure, such as shortness of breath and leg swelling.


Pericardial mesothelioma can lead to secondary complications, and these complications are sometimes the first symptom of the disease. These can include:

  • Abnormal heart rhythms
  • Cardiac tamponade
  • Sudden death (usually due to an arrhythmia): The risk of sudden death is not an uncommon complication, and roughly 70% of pericardial mesotheliomas are only diagnosed after death during an autopsy.


While pleural and peritoneal mesotheliomas are strongly associated with asbestos exposure, the link is weaker with pericardial mesothelioma. Though some associations have been noted, the cause of these tumors is usually unknown. This is particularly true when the tumors begin in young people. The disease does not appear to be associated with smoking.

Asbestos Exposure

While frequently attributed to asbestos exposure, results of recent investigations question the relationship of both pericardial and paratesticular mesotheliomas with asbestos, at least in the United States.

According to a 2017 study, a substantial number of pericardial mesotheliomas occur in people who have had no known asbestos exposure. In addition, in evaluating large groups of people who have had heavy asbestos exposure, no cases of pericardial mesothelioma were reported.

Unlike pleural mesothelioma, the incidence of pericardial mesothelioma does not correspond to trends in the use of asbestos over time, and the disease is not seen primarily in men.

Another 2016 study looked at people with pericardial mesothelioma in different populations and compared them with people who were diagnosed with pleural mesothelioma. The assumption was that, if asbestos plays a role in the causation of pericardial mesothelioma as it does with pleural mesothelioma, the incidence of both diseases should be elevated in regions where asbestos exposure is higher. Unlike higher rates of pleural mesothelioma (twice as high) in regions such as San Francisco and Seattle, however, the incidence of pericardial mesothelioma was not increased in these areas.

Unlike these U.S. studies, however, an Italian study did find a significant association between asbestos exposure and pericardial mesothelioma. Of people diagnosed in the Lombardy region who were available for interview, five out of seven had experienced occupational exposure to asbestos.

Medical Radiation

Medical radiation to the chest for lymphoma or breast cancer has been associated with mesothelioma in general, but only a few reports suggesting an association with pericardial mesothelioma have been published.

When mesothelioma occurs after radiation therapy, there is usually a latency period of 15 years to 25 years.


Research looking at the genetics of cancer is young, especially with regard to mesothelioma. That said, associations with some chromosomal anomalies have been seen, and there is some evidence that the disease may be associated with hereditary BRCA1 mutations in at least some cases.


The diagnosis of pericardial mesothelioma can be very difficult, and it's not uncommon for the diagnosis to be made "accidentally," such as when a procedure is done to drain a pericardial effusion or during open heart surgery.

A combination of studies, such as computed tomography (CT), magnetic resonance imaging (MRI), and echocardiogram followed by biopsy, is often needed to make a definitive diagnosis.

Imaging Studies

A regular chest X-ray may lead to suspicion but is not very helpful in diagnosis. A chest CT or MRI can be very helpful, both to identify the tumor in the pericardium and to look for spread of the tumor to nearby structures. A PET scan may also be used as an added test.


An echocardiogram is often done, though the accuracy alone is low unless combined with imaging studies.

When a pericardial effusion is seen (fluid between the two layers of pericardium), a pericardiocentesis is often done. A pericardiocentesis is a test in which a long, thin needle is inserted into the pericardial space to withdraw fluid. Fluid may be removed to improve symptoms from a large pericardial effusion and/or to obtain a sample to look for the presence of cancer cells.

When positive for mesothelioma cells, a pericardiocentesis may lead to the diagnosis, but cancer cells are found in only 25% of these procedures in people with the cancer.


A biopsy is usually needed to confirm a diagnosis, but can be challenging due to the location of the pericardium around the heart and near major blood vessels.

A needle biopsy is commonly done, though other approaches may be needed. Pericardioscopy is a minimally invasive procedure (similar to a laparascopy in the abdomen) that may be used to obtain a biopsy sample.

Even when a biopsy sample is obtained and viewed under the microscope, the diagnosis may be difficult, and special testing (immunohistochemical antibody testing) may be necessary to make the diagnosis.


A biopsy sample can also be used to determine the subtype of mesothelioma. The three primary types include:

  • Epithelioid
  • Sarcomatoid (the poorest prognosis)
  • Mixed

Biomarkers and Molecular Testing

Since pericardial mesothelioma is so rare, less is known about biomarkers and molecular testing than with many other types of cancer, but some advances are being made. Currently, these tests may be used to follow treatment, but it's hoped that further research will lead to a screening tool in the future.

Differential Diagnosis

There are a number of conditions that may resemble pericardial mesothelioma with regard to either symptoms or findings on diagnostic tests. Some of these include:

  • Constrictive pericarditis
  • Metastases to the pericardium (for example, from lung cancer or breast cancer)
  • Heart failure
  • Other pericardial tumors
  • Lupus serositis of the pericardium: More than one person with pericardial mesothelioma has been first (erroneously) diagnosed with lupus serositis.


Much of what is known about treating pericardial mesothelioma stems from research on pleural mesothelioma, and there are currently no standard therapies.

Overall, surgery is the treatment of choice when the cancer is localized to the pericardium. Pericardial mesotheliomas can spread locally to involve the conduction system of the heart and major vessels, as well as distantly to the liver or lungs.

When the cancer has spread, chemotherapy may lengthen survival, and clinical trials are considered important with regard to treatment.


Pericardiectomy, or surgery to remove the pericardium is ideal when the cancer is caught early. That said, when these cancers are diagnosed roughly 25% to 45% will have spread to the liver or lungs, and others may have spread locally near the heart so that surgery is not possible.

When surgery is done, adjuvant treatment with chemotherapy (chemotherapy after surgery to "clean up" any leftover cancer cells) and/or radiation is often considered.


Radiation alone does not appear to make a difference in survival, but may help with pain management due to the tumor. It's important to note that with cancers such as this, the importance of addressing pain can't be overstated.


Chemotherapy using the medications Platinol (cisplatin) and Alimta (pemetrexed) has improved the length of survival for some people with pericardial mesothelioma, and in at least one case, has led to prolonged progression-free survival.

Clinical Trials

At the current time, there are relatively few approved options for treating pericardial mesothelioma, and many oncologists recommend looking into clinical trials.

Fortunately, there are several different types of treatment that are beings studied (though several of these are for mesothelioma in general, rather than specifically pericardial mesothelioma). Some examples include:

  • Immunotherapy: There are different types of immunotherapy. Checkpoint inhibitors are the category of drugs for which responses have sometimes been seen with advanced lung cancer, melanoma, and other cancers. One study looking at Opdivo (pembrolizumab) is ongoing. Oncovirus therapy (using the measles virus) is also being studied.
  • Angiogenesis inhibitors: In order for cancers to grow, they need to form/recruit new blood vessels, a process called angiogenesis. The drug Avastin (bevacizumab) has been used along with chemotherapy in pleural mesothelioma with improved survival.
  • Arginine deprivation therapy
  • Targeted therapy: The drug nintedanib (a drug that targets the VEGF receptor) is being studied, with some improvement in progression-free survival in early studies.


At the current time, the prognosis for pericardial mesothelioma remains poor. A 2019 report of 103 cases found that the overall median survival (the time after which 50% of people have died and 50% are still alive) was six months. For those who received chemotherapy, the median survival was 13 months.

The prognosis is better for those who have the epitheliod rather than mesotheliod subtype, and for people who have tumors that have not spread to the region around the heart (the mediastinum) or distant organs.

It is important to note that, while the prognosis of pericardial mesothelioma is poor, there are some long term survivors. For example, a case report details a 59-year-old patient who underwent surgery and chemotherapy and remained alive and without symptoms three years after surgery.

The statistics we have available today do not take into account more recent approaches in clinical trials, and things could change in the future. It's also important to note that everyone is different. People are not statistics.


Being diagnosed with any cancer is challenging, but with a cancer that is both rare and has few approved treatments such as pericardial mesothelioma, it can be heartwrenching.

Without raising false hope it's important to note that the treatments and survival rates for cancer in general are improving, and even with mesothelioma there are several clinical trials in progress looking for newer and better therapies.

It's important to talk to your healthcare provider about the option of clinical trials. Clinical trials are changing relative to the approach in the past. Many of these newer drugs have been designed specifically to address specific pathways in the growth of cancer, and as such, may be more likely to have an impact on a cancer than drugs that were studied in the past.

You may also wish to consider a second opinion, preferably at one of the larger cancer centers that has healthcare providers who specialize in the treatment of mesothelioma.

For Loved Ones

With cancers such as mesothelioma that have been associated with specific exposures such as asbestos (even though this appears to be less the case with pericardial mesothelioma), many people question the potential causes.

While this, and advocacy in general, is extremely important, efforts to figure out the causes and make a difference are probably not what your loved one needs from you at this time. Even if you are feeling driven to investigate what may have made your loved one ill, try to focus on simply loving her for now.

A Word From Verywell

Pericardial mesothelioma is a very rare tumor with few treatment options. That said, just as advances have been made with several other similarly difficult to treat cancers, there is hope that newer approaches, such as immunotherapy, will lead to better options in the near future.

14 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Chung SM, Choi SJ, Kim MJ, et al. Positive response of a primary malignant pericardial mesothelioma to pemetrexed plus cisplatin followed by pemetrexed maintenance chemotherapy: A case report. Oncology Letters. 2016;12(1):213-216. doi:10.3892/ol.2016.4598

  2. McGehee E, Gerber DE, Reisch J, Dowell JE. Treatment and outcomes of primary pericardial mesothelioma: A contemporary review of 103 published cases. Clinical Lung Cancer. 2019;20(2):e152-e157. doi:10.1016/j.cllc.2018.11.008

  3. Istomin V, Blondheim DS, Meissel SR, et al. Pericardial effusion due to primary malignant pericardial mesothelioma: A common finding but an uncommon cause. Case Reports in Medicine. 2016:4810901. doi:10.1155/2016/4810901

  4. American Society of Clinical Oncology. Mesothelioma: Risk factors.

  5. Mezei G, Chang ET, Mowat FS, Moolgavkar SH. Epidemiology of mesothelioma of the pericardium and tunica vaginalis testis. Annals of Epidemiology. 2017;27(5):348-359.e11. doi:10.1016/j.annepidem.2017.04.001

  6. Lowry SJ, Weiss NS. Geographic distribution of incidence of pericardial and paratesticular mesotheliomas in the USA. Cancer Causes and Control. 2016;27(12):1487-1489. doi:10.1007/s10552-016-0825-3

  7. Mensi C, Giacomini S, Sieno C, Consonni D, Riboldi L. Pericardial mesothelioma and asbestos exposure. International Journal of Hygeine and Environmental Health. 2011;214(3):276-9. doi:10.1016/j.ijheh.2010.11.005

  8. Naeini YB, Arcega R, Hirschowitz S, Rao N, Xu H. Post-irradiation pericardial malignant mesothelioma with deletion of p16: A case report. Cancer Biology and Medicine. 2018;15(1):97-102. doi:10.20892/j.issn.2095-3941.2017.0169

  9. Pillappa R, Maleszewski JJ, Sukov WR, et al. Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma. Am J Surg Pathol. 2018;42(2):256-263. doi:10.1097/PAS.0000000000000976

  10. Cao S, Jin S, Cao J, et al. Malignant pericardial mesothelioma : A systematic review of current practice. Herz. 2018;43(1):61-68. doi:10.1007/s00059-016-4522-5

  11. Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surgical Pathology Clinics. 2020;13(1):73-89. doi:10.1016/j.path.2019.10.001

  12. Mensi C, Romano A, Berti A, Dore R, Riboldi L. A second case of pericardial mesothelioma mimicking systemic lupus erythematosus in the literature in over 30 years: a case report. Journal of Medical Case Reports. 2017;11(1):85. doi:10.1186/s13256-017-1237-z

  13. Mutti L, Peikert T, Robinson BWS, et al. Scientific advances and new frontiers in mesothelioma therapeutics. Journal of Thoracic Oncology. 2018;13(9):1269-1283. doi:10.1016/j.jtho.2018.06.011

  14. Fujita K, Hata M, Sezai A, Minami K. Three-year survival after surgery for primary malignant pericardial mesothelioma: Report of a case. Surgery Today. 2014;44(5):948-51. doi:10.1007/s00595-013-0511-y

Additional Reading

By Lynne Eldridge, MD
 Lynne Eldrige, MD, is a lung cancer physician, patient advocate, and award-winning author of "Avoiding Cancer One Day at a Time."